Genzyme's Lemtrada Approved in Canada for Treatment of MS
December 13, 2013 at 08:02 AM EST
Genzyme, a Sanofi company (NYSE: SNY ), announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis (RRMS),